{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:36:03Z","timestamp":1794569763575,"version":"4.9.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>It is widely recognized that luteinizing hormone (LH) activity is pivotal during folliculogenesis. Nonetheless, the use of LH during ovarian stimulation remains a matter of debate. Indeed, women with good LH function are able to sustain follicle growth and maturation during ovarian stimulation carried out with regimens based on follicle-stimulating hormone (FSH) alone. However, evidence exists that LH activity could be necessary in specific infertile subgroups undergoing assisted reproduction treatment (ART) who are characterized by a functional or constitutive LH deficiency. For instance, women with reduced sensitivity to gonadotropins, also called hypo-responders, usually present with a genetic condition that could impair the function of LH. Furthermore, women of advanced reproductive age present a less functional LH system and consequently reduced androgen production. Reduced ovarian sensitivity and advanced reproductive age represent the main criteria proposed by the POSEIDON group to identify women with impaired prognosis when undergoing ART. Hypogonadotropic hypogonadal women are characterized by undetectable LH levels, thus the addition of LH activity during stimulation is mandatory to achieve satisfactory follicular recruitment. The aim of the present review is to describe the role of recombinant LH in ovarian stimulation, identifying the specific infertile population for whom LH supplementation could improve the outcome of ART.<\/jats:p>","DOI":"10.1186\/s12958-025-01361-8","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T02:59:47Z","timestamp":1741575587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The role of recombinant LH in ovarian stimulation: what\u2019s new?"],"prefix":"10.1186","volume":"23","author":[{"given":"Carlo","family":"Alviggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Vigilante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cariati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-020X","authenticated-orcid":false,"given":"Alessandro","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Humaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"1361_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0303-7207(94)90278-X","volume":"100","author":"SG Hillier","year":"1994","unstructured":"Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the two-cell, two-gonadotrophin model revisited. Mol Cell Endocrinol. 1994;100:51\u20134.","journal-title":"Mol Cell Endocrinol"},{"key":"1361_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0022-4731(79)90014-1","volume":"11","author":"KJ Ryan","year":"1979","unstructured":"Ryan KJ. Granulosa-thecal cell interaction in ovarian steroidogenesis. J Steroid Biochem. 1979;11:799\u2013800.","journal-title":"J Steroid Biochem"},{"key":"1361_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1472-6483(10)60865-6","volume":"12","author":"C Alviggi","year":"2006","unstructured":"Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online. 2006;12:221\u201333.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S1472-6483(10)60347-1","volume":"15","author":"R Palermo","year":"2007","unstructured":"Palermo R. Differential actions of FSH and LH during folliculogenesis. Reprod Biomed Online. 2007;15:326\u201337.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR5","doi-asserted-by":"publisher","first-page":"s33","DOI":"10.1016\/S1472-6483(11)60007-2","volume":"22","author":"C Alviggi","year":"2011","unstructured":"Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Who needs LH in ovarian stimulation? Reprod Biomed Online. 2011;22:s33\u201341.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR6","doi-asserted-by":"publisher","first-page":"E1524","DOI":"10.1210\/jc.2012-1427","volume":"97","author":"JV Jeppesen","year":"2012","unstructured":"Jeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini R, et al. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol Metab. 2012;97:E1524\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1043-2760(03)00085-7","volume":"14","author":"M Filicori","year":"2003","unstructured":"Filicori M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab. 2003;14:267\u201373.","journal-title":"Trends Endocrinol Metab"},{"key":"1361_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.tem.2018.01.007","volume":"29","author":"L Casarini","year":"2018","unstructured":"Casarini L, Santi D, Simoni M, Pot\u00ec F. Spare luteinizing hormone receptors: facts and fiction. Trends Endocrinol Metab. 2018;29:208\u201317.","journal-title":"Trends Endocrinol Metab"},{"key":"1361_CR9","first-page":"228","volume":"84","author":"MW Sullivan","year":"1999","unstructured":"Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab. 1999;84:228\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1210\/jcem.87.3.8322","volume":"87","author":"M Filicori","year":"2002","unstructured":"Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, et al. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab. 2002;87:1156\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mce.2015.12.008","volume":"422","author":"L Casarini","year":"2016","unstructured":"Casarini L, Riccetti L, De Pascali F, Nicoli A, Tagliavini S, Trenti T, et al. Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro. Mol Cell Endocrinol. 2016;422:103\u201314.","journal-title":"Mol Cell Endocrinol"},{"key":"1361_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.fertnstert.2006.06.059","volume":"87","author":"G Ruvolo","year":"2007","unstructured":"Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril. 2007;87:542\u20136.","journal-title":"Fertil Steril"},{"key":"1361_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/cdd.2016.97","volume":"24","author":"V Rossi","year":"2017","unstructured":"Rossi V, Lispi M, Longobardi S, Mattei M, Di Rella F, Salustri A, et al. LH prevents cisplatin-induced apoptosis in oocytes and preserves female fertility in mouse. Cell Death Differ. 2017;24:72\u201382.","journal-title":"Cell Death Differ"},{"key":"1361_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1677\/jme.0.0120283","volume":"12","author":"ZH Huang","year":"1994","unstructured":"Huang ZH, Clayton PE, Brady G, Morris ID. Insulin-like growth factor-I gene expression in human granulosa-lutein cells. J Mol Endocrinol. 1994;12:283\u201391.","journal-title":"J Mol Endocrinol"},{"key":"1361_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/138920112799361945","volume":"13","author":"E Munoz","year":"2012","unstructured":"Munoz E, Bosch E, Fernandez I, Portela S, Ortiz G, Remohi J, et al. The role of LH in ovarian stimulation. Curr Pharm Biotechnol. 2012;13:409\u201316.","journal-title":"Curr Pharm Biotechnol"},{"key":"1361_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s10815-018-1248-8","volume":"35","author":"S Sacchi","year":"2018","unstructured":"Sacchi S, Sena P, Degli Esposti C, Lui J, La Marca A. Evidence for expression and functionality of FSH and LH\/hCG receptors in human endometrium. J Assist Reprod Genet. 2018;35:1703\u201312.","journal-title":"J Assist Reprod Genet"},{"key":"1361_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1071\/RD11241","volume":"25","author":"V Gridelet","year":"2013","unstructured":"Gridelet V, Tsampalas M, Berndt S, Hagelstein M-T, Charlet-Renard C, Conrath V, et al. Evidence for cross-talk between the LH receptor and LH during implantation in mice. Reprod Fertil Dev. 2013;25:511\u201322.","journal-title":"Reprod Fertil Dev"},{"key":"1361_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mce.2006.10.019","volume":"269","author":"T Pakarainen","year":"2007","unstructured":"Pakarainen T, Ahtiainen P, Zhang F-P, Rulli S, Poutanen M, Huhtaniemi I. Extragonadal LH\/hCG action\u2013not yet time to rewrite textbooks. Mol Cell Endocrinol. 2007;269:9\u201316.","journal-title":"Mol Cell Endocrinol"},{"key":"1361_CR19","first-page":"33","volume":"43","author":"AJ Ziecik","year":"1992","unstructured":"Ziecik AJ, Derecka-Reszka K, Rzucid\u0142o SJ. Extragonadal gonadotropin receptors, their distribution and function. J Physiol Pharmacol. 1992;43:33\u201349.","journal-title":"J Physiol Pharmacol"},{"key":"1361_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mce.2006.08.016","volume":"269","author":"AJ Ziecik","year":"2007","unstructured":"Ziecik AJ, Kaczmarek MM, Blitek A, Kowalczyk AE, Li X, Rahman NA. Novel biological and possible applicable roles of LH\/hCG receptor. Mol Cell Endocrinol. 2007;269:51\u201360.","journal-title":"Mol Cell Endocrinol"},{"key":"1361_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41586-022-04463-0","volume":"603","author":"J Xiong","year":"2022","unstructured":"Xiong J, Kang SS, Wang Z, Liu X, Kuo T-C, Korkmaz F, et al. FSH blockade improves cognition in mice with Alzheimer\u2019s disease. Nature. 2022;603:470\u20136.","journal-title":"Nature"},{"key":"1361_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature22342","volume":"546","author":"P Liu","year":"2017","unstructured":"Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature. 2017;546:107\u201312.","journal-title":"Nature"},{"key":"1361_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2006.01.051","volume":"125","author":"L Sun","year":"2006","unstructured":"Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, et al. FSH directly regulates bone mass. Cell. 2006;125:247\u201360.","journal-title":"Cell"},{"key":"1361_CR24","doi-asserted-by":"publisher","first-page":"101596","DOI":"10.1016\/j.beem.2021.101596","volume":"36","author":"A Rivero-M\u00fcller","year":"2022","unstructured":"Rivero-M\u00fcller A, Huhtaniemi I. Genetic variants of gonadotrophins and their receptors: impact on the diagnosis and management of the infertile patient. Best Pract Res Clin Endocrinol Metab. 2022;36:101596.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1361_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fendo.2019.00032","volume":"10","author":"M Chrusciel","year":"2019","unstructured":"Chrusciel M, Ponikwicka-Tyszko D, Wolczynski S, Huhtaniemi I, Rahman NA. Extragonadal FSHR expression and function-Is it real? Front Endocrinol (Lausanne). 2019;10:32.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.12703\/r\/10-41","volume":"10","author":"L Casarini","year":"2021","unstructured":"Casarini L, Simoni M. Recent advances in understanding gonadotropin signaling. Fac Rev. 2021;10:41.","journal-title":"Fac Rev"},{"key":"1361_CR27","doi-asserted-by":"publisher","first-page":"8624","DOI":"10.1038\/s41598-022-12495-9","volume":"12","author":"ON Mann","year":"2022","unstructured":"Mann ON, Kong C-S, Lucas ES, Brosens JJ, Hanyaloglu AC, Brighton PJ. Expression and function of the luteinizing hormone choriogonadotropin receptor in human endometrial stromal cells. Sci Rep. 2022;12:8624.","journal-title":"Sci Rep"},{"key":"1361_CR28","doi-asserted-by":"publisher","first-page":"37095","DOI":"10.1038\/srep37095","volume":"6","author":"J Stelmaszewska","year":"2016","unstructured":"Stelmaszewska J, Chrusciel M, Doroszko M, Akerfelt M, Ponikwicka-Tyszko D, Nees M, et al. Revisiting the expression and function of follicle-stimulation hormone receptor in human umbilical vein endothelial cells. Sci Rep. 2016;6:37095.","journal-title":"Sci Rep"},{"key":"1361_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/andr.13335","volume":"11","author":"A Elenkov","year":"2023","unstructured":"Elenkov A, Wirestrand E, Hagsund A, Huhtaniemi I, Giwercman YL, Giwercman A. Non-reproductive effects of follicle-stimulating hormone in young men. Andrology. 2023;11:471\u20137.","journal-title":"Andrology"},{"key":"1361_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:560\u201379.","journal-title":"Hum Reprod Update"},{"key":"1361_CR31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/humrep\/deab065","volume":"36","author":"E Bosch","year":"2021","unstructured":"Bosch E, Alviggi C, Lispi M, Conforti A, Hanyaloglu AC, Chuderland D, et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod. 2021;36:1469\u201380.","journal-title":"Hum Reprod"},{"key":"1361_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/humrep\/15.5.1003","volume":"15","author":"LG Westergaard","year":"2000","unstructured":"Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003\u20138.","journal-title":"Hum Reprod"},{"key":"1361_CR33","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.fertnstert.2018.01.003","volume":"109","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, B\u00fchler K, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018;109:644\u201364.","journal-title":"Fertil Steril"},{"key":"1361_CR34","first-page":"279","volume":"56","author":"G Griesinger","year":"2011","unstructured":"Griesinger G, Shapiro DB. Luteinizing hormone add-back: is it needed in controlled ovarian stimulation, and if so. when? J Reprod Med. 2011;56:279\u2013300.","journal-title":"when? J Reprod Med"},{"key":"1361_CR35","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/humrep\/der092","volume":"26","author":"AP Ferraretti","year":"2011","unstructured":"Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of poor response to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616\u201324.","journal-title":"Hum Reprod"},{"key":"1361_CR36","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/humrep\/deu135","volume":"29","author":"A Papathanasiou","year":"2014","unstructured":"Papathanasiou A. Implementing the ESHRE poor responder criteria in research studies: methodological implications. Hum Reprod. 2014;29:1835\u20138.","journal-title":"Hum Reprod"},{"key":"1361_CR37","doi-asserted-by":"publisher","first-page":"587051","DOI":"10.3389\/fendo.2021.587051","volume":"12","author":"SC Esteves","year":"2021","unstructured":"Esteves SC, Conforti A, Sunkara SK, Carbone L, Picarelli S, Vaiarelli A, et al. Improving reporting of clinical studies using the POSEIDON criteria: POSORT guidelines. Front Endocrinol (Lausanne). 2021;12:587051.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR38","unstructured":"Esteves SC, Yarali H, Vuong LN, Conforti A, Humaidan P, Alviggi C. POSEIDON groups and their distinct reproductive outcomes: effectiveness and cost-effectiveness insights from real-world data research. Best Pract Res Clin Obstet Gynaecol. 2022;S1521-6934(22)00080\u2009\u2013\u20093."},{"key":"1361_CR39","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","volume":"105","author":"C Alviggi","year":"2016","unstructured":"POSEIDON Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number), Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105:1452\u20133.","journal-title":"Fertil Steril"},{"key":"1361_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.rbmo.2017.03.009","volume":"34","author":"G Bozdag","year":"2017","unstructured":"Bozdag G, Polat M, Yarali I, Yarali H. Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria. Reprod Biomed Online. 2017;34:639\u201344.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fendo.2020.00208","volume":"11","author":"A Romito","year":"2020","unstructured":"Romito A, Bardhi E, Errazuriz J, Blockeel C, Santos-Ribeiro S, Vos MD, et al. Heterogeneity among poor ovarian responders according to Bologna criteria results in diverging cumulative live birth rates. Front Endocrinol (Lausanne). 2020;11:208.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR42","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dex208","volume":"32","author":"P Humaidan","year":"2017","unstructured":"Humaidan P, Chin W, Rogoff D, D\u2019Hooghe T, Longobardi S, Hubbard J, et al. Efficacy and safety of follitropin alfa\/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32:544\u201355.","journal-title":"Hum Reprod"},{"key":"1361_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rbmo.2018.03.013","volume":"37","author":"P Lehert","year":"2018","unstructured":"Lehert P, Chin W, Schertz J, D\u2019Hooghe T, Alviggi C, Humaidan P. Predicting live birth for poor ovarian responders: the PROsPeR concept. Reprod Biomed Online. 2018;37:43\u201352.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR44","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/humrep\/deab050","volume":"36","author":"P Lehert","year":"2021","unstructured":"Lehert P, Arvis P, Avril C, Massin N, Parinaud J, Porcu G, et al. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome. Hum Reprod. 2021;36:1600\u201310.","journal-title":"Hum Reprod"},{"key":"1361_CR45","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.rbmo.2020.08.035","volume":"42","author":"P Arvis","year":"2021","unstructured":"Arvis P, Massin N, Lehert P. Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: a large, real-world study. Reprod Biomed Online. 2021;42:546\u201354.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3389\/fendo.2018.00589","volume":"9","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, et al. Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the Follicle-To-Oocyte (FOI) index. Front Endocrinol (Lausanne). 2018;9:589.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR47","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.fertnstert.2004.06.041","volume":"82","author":"AP Ferraretti","year":"2004","unstructured":"Ferraretti AP, Gianaroli L, Magli MC, D\u2019angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82:1521\u20136.","journal-title":"Fertil Steril"},{"key":"1361_CR48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/humrep\/deh625","volume":"20","author":"G De Placido","year":"2005","unstructured":"De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod. 2005;20:390\u20136.","journal-title":"Hum Reprod"},{"key":"1361_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.23736\/S0031-0808.18.03511-5","volume":"61","author":"A Conforti","year":"2019","unstructured":"Conforti A, Esteves SC, Picarelli S, Iorio G, Rania E, Zullo F, et al. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. Panminerva Med. 2019;61:24\u20139.","journal-title":"Panminerva Med"},{"key":"1361_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fendo.2019.00439","volume":"10","author":"P Humaidan","year":"2019","unstructured":"Humaidan P, La Marca A, Alviggi C, Esteves SC, Haahr T. Future perspectives of POSEIDON stratification for clinical practice and research. Front Endocrinol (Lausanne). 2019;10:439.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/09513590.2014.965675","volume":"31","author":"F Yaz\u0131c\u0131 Y\u0131lmaz","year":"2015","unstructured":"Yaz\u0131c\u0131 Y\u0131lmaz F, G\u00f6rkemli H, \u00c7olako\u011flu MC, Aktan M, Gezgin\u00e7 K. The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation. Gynecol Endocrinol. 2015;31:141\u20134.","journal-title":"Gynecol Endocrinol"},{"key":"1361_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12958-019-0460-4","volume":"17","author":"A Conforti","year":"2019","unstructured":"Conforti A, Esteves SC, Di Rella F, Strina I, De Rosa P, Fiorenza A, et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2019;17:18.","journal-title":"Reprod Biol Endocrinol"},{"issue":"Suppl 1","key":"1361_CR53","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S1472-6483(11)60011-4","volume":"22","author":"C Alviggi","year":"2011","unstructured":"Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online. 2011;22(Suppl 1):S67\u201372.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1477-7827-11-51","volume":"11","author":"C Alviggi","year":"2013","unstructured":"Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De Rosa P, et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol. 2013;11:51\u201351.","journal-title":"Reprod Biol Endocrinol"},{"key":"1361_CR55","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/01443615.2020.1821619","volume":"41","author":"Y Ku","year":"2021","unstructured":"Ku Y, Hong MA, Chae SJ, Lim KS, Lee W-D, Lim JH, et al. The effects of luteinising hormone gene polymorphism on the outcomes of in vitro fertilisation and embryo transfer. J Obstet Gynaecol. 2021;41:1092\u20136.","journal-title":"J Obstet Gynaecol"},{"key":"1361_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.fertnstert.2004.06.076","volume":"83","author":"LI Barmat","year":"2005","unstructured":"Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist\/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist\/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril. 2005;83:321\u201330.","journal-title":"Fertil Steril"},{"key":"1361_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000509162","volume":"85","author":"S Kol","year":"2020","unstructured":"Kol S. LH supplementation in ovarian stimulation for IVF: the individual, LH deficient, patient perspective. Gynecol Obstet Invest. 2020;85:307\u201311.","journal-title":"Gynecol Obstet Invest"},{"key":"1361_CR58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1472-6483(10)60340-9","volume":"15","author":"JA Garcia-Velasco","year":"2007","unstructured":"Garcia-Velasco JA, Coelingh Bennink HJT, Epifanio R, Escudero E, Pellicer A, Sim\u00f3n C. High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist. Reprod Biomed Online. 2007;15:280\u20137.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejogrb.2018.01.025","volume":"222","author":"GA Ramaraju","year":"2018","unstructured":"Ramaraju GA, Cheemakurthi R, Prathigudupu K, Balabomma KL, Kalagara M, Thota S, et al. Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: a cross-sectional study. Eur J Obstet Gynecol Reprod Biol. 2018;222:119\u201325.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1361_CR60","doi-asserted-by":"publisher","first-page":"628169","DOI":"10.3389\/fendo.2021.628169","volume":"12","author":"GA Ramaraju","year":"2021","unstructured":"Ramaraju GA, Cheemakurthi R, Kalagara M, Prathigudupu K, Balabomma KL, Mahapatro P, et al. Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study. Front Endocrinol (Lausanne). 2021;12:628169.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR61","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fendo.2017.00376","volume":"8","author":"SG Kristensen","year":"2017","unstructured":"Kristensen SG, Mamsen LS, Jeppesen JV, B\u00f8tkj\u00e6r JA, Pors SE, Borgbo T, et al. Hallmarks of human small antral follicle development: implications for regulation of ovarian steroidogenesis and selection of the dominant follicle. Front Endocrinol (Lausanne). 2017;8:376.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR62","doi-asserted-by":"publisher","first-page":"12907","DOI":"10.1038\/s41598-020-69325-z","volume":"10","author":"S Marchiani","year":"2020","unstructured":"Marchiani S, Tamburrino L, Benini F, Pallecchi M, Bignozzi C, Conforti A, et al. LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women. Sci Rep. 2020;10:12907.","journal-title":"Sci Rep"},{"key":"1361_CR63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.fertnstert.2013.12.032","volume":"101","author":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee","year":"2014","unstructured":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Comm Opin 589 Fertil Steril. 2014;101:633\u20134.","journal-title":"Comm Opin 589 Fertil Steril"},{"key":"1361_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1477-7827-7-101","volume":"7","author":"C Alviggi","year":"2009","unstructured":"Alviggi C, Humaidan P, Howles CM, Tredway D, Hillier SG. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol. 2009;7:101\u2013101.","journal-title":"Reprod Biol Endocrinol"},{"key":"1361_CR65","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10815-013-0083-1","volume":"30","author":"B Wiweko","year":"2013","unstructured":"Wiweko B, Prawesti DMP, Hestiantoro A, Sumapraja K, Natadisastra M, Baziad A. Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-mullerian hormone. J Assist Reprod Genet. 2013;30:1563\u20137.","journal-title":"J Assist Reprod Genet"},{"key":"1361_CR66","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/humrep\/deab152","volume":"36","author":"SC Esteves","year":"2021","unstructured":"Esteves SC, Yarali H, Vuong LN, Carvalho JF, \u00d6zbek \u0130Y, Polat M, et al. Cumulative delivery rate per aspiration IVF\/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. Hum Reprod. 2021;36:2157\u201369.","journal-title":"Hum Reprod"},{"key":"1361_CR67","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.rbmo.2020.08.003","volume":"41","author":"R Yang","year":"2020","unstructured":"Yang R, Zhang C, Chen L, Wang Y, Li R, Liu P, et al. Cumulative live birth rate of low prognosis patients with POSEIDON stratification: a single-centre data analysis. Reprod Biomed Online. 2020;41:834\u201344.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR68","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.rbmo.2012.02.009","volume":"24","author":"B Ata","year":"2012","unstructured":"Ata B, Kaplan B, Danzer H, Glassner M, Opsahl M, Tan SL, et al. Array CGH analysis shows that aneuploidy is not related to the number of embryos generated. Reprod Biomed Online. 2012;24:614\u201320.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.23736\/S0031-0808.18.03507-3","volume":"61","author":"SC Esteves","year":"2019","unstructured":"Esteves SC, Carvalho JF, Martinhago CD, Melo AA, Bento FC, Humaidan P, et al. Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. Panminerva Med. 2019;61:3\u201310.","journal-title":"Panminerva Med"},{"key":"1361_CR70","doi-asserted-by":"publisher","first-page":"797243","DOI":"10.3389\/fendo.2021.797243","volume":"12","author":"A Guligowska","year":"2021","unstructured":"Guligowska A, Chrzastek Z, Pawlikowski M, Pig\u0142owska M, Pisarek H, Winczyk K, et al. Gonadotropins at advanced age - perhaps they are not so bad? Correlations between gonadotropins and sarcopenia indicators in older adults. Front Endocrinol (Lausanne). 2021;12:797243.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1361_CR71","first-page":"1429","volume":"80","author":"B Zumoff","year":"1995","unstructured":"Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995;80:1429\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR72","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1210\/jc.2005-0212","volume":"90","author":"SL Davison","year":"2005","unstructured":"Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90:3847\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR73","first-page":"1038","volume":"81","author":"NA Klein","year":"1996","unstructured":"Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR74","doi-asserted-by":"crossref","unstructured":"Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015;CD009749.","DOI":"10.1002\/14651858.CD009749.pub2"},{"key":"1361_CR75","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.rbmo.2017.07.012","volume":"35","author":"M von Wolff","year":"2017","unstructured":"von Wolff M, Stute P, Eisenhut M, Marti U, Bitterlich N, Bersinger NA. Serum and follicular fluid testosterone concentrations do not correlate, questioning the impact of androgen supplementation on the follicular endocrine milieu. Reprod Biomed Online. 2017;35:616\u201323.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR76","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/humrep\/deu044","volume":"29","author":"M von Wolff","year":"2014","unstructured":"von Wolff M, Kollmann Z, Fl\u00fcck CE, Stute P, Marti U, Weiss B, et al. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF. Hum Reprod. 2014;29:1049\u201357.","journal-title":"Hum Reprod"},{"key":"1361_CR77","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/humrep\/dev038","volume":"30","author":"TNL Vuong","year":"2015","unstructured":"Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged\u2009\u2265\u200935 years: a randomized controlled trial. Hum Reprod. 2015;30:1188\u201395.","journal-title":"Hum Reprod"},{"key":"1361_CR78","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.fertnstert.2010.10.021","volume":"95","author":"E Bosch","year":"2011","unstructured":"Bosch E, Labarta E, Crespo J, Sim\u00f3n C, Remoh\u00ed J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011;95:1031\u20136.","journal-title":"Fertil Steril"},{"key":"1361_CR79","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1093\/humrep\/det266","volume":"28","author":"TE K\u00f6nig","year":"2013","unstructured":"K\u00f6nig TE, van der Houwen LEE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WKH, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF\/ICSI: a randomized controlled multicentre study. Hum Reprod. 2013;28:2804\u201312.","journal-title":"Hum Reprod"},{"key":"1361_CR80","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12958-021-00759-4","volume":"19","author":"A Conforti","year":"2021","unstructured":"Conforti A, Esteves SC, Humaidan P, Longobardi S, D\u2019Hooghe T, Orvieto R, et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021;19:91.","journal-title":"Reprod Biol Endocrinol"},{"key":"1361_CR81","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s43032-019-00137-x","volume":"27","author":"A Arroyo","year":"2020","unstructured":"Arroyo A, Kim B, Yeh J. Luteinizing hormone action in human oocyte maturation and quality: signaling pathways, regulation, and clinical impact. Reprod Sci. 2020;27:1223\u201352.","journal-title":"Reprod Sci"},{"key":"1361_CR82","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/humrep\/17.4.1017","volume":"17","author":"C Mendoza","year":"2002","unstructured":"Mendoza C, Ruiz-Requena E, Ortega E, Cremades N, Martinez F, Bernabeu R, et al. Follicular fluid markers of oocyte developmental potential. Hum Reprod. 2002;17:1017\u201322.","journal-title":"Hum Reprod"},{"key":"1361_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1472-6483(10)61729-4","volume":"7","author":"J Tesarik","year":"2003","unstructured":"Tesarik J, Hazout A, Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online. 2003;7:59\u201364.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR84","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1472-6483(10)61717-8","volume":"6","author":"A Herrler","year":"2003","unstructured":"Herrler A, von Rango U, Beier HM. Embryo-maternal signalling: how the embryo starts talking to its mother to accomplish implantation. Reprod Biomed Online. 2003;6:244\u201356.","journal-title":"Reprod Biomed Online"},{"key":"1361_CR85","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1093\/humrep\/deq125","volume":"25","author":"E Bosch","year":"2010","unstructured":"Bosch E, Labarta E, Crespo J, Sim\u00f3n C, Remoh\u00ed J, Jenkins J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010;25:2092\u2013100.","journal-title":"Hum Reprod"},{"key":"1361_CR86","doi-asserted-by":"crossref","unstructured":"Xu B, Li Z, Zhang H, Jin L, Li Y, Ai J et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles. Fertil Steril. 2012;97:1321\u20137.e1\u20134.","DOI":"10.1016\/j.fertnstert.2012.03.014"},{"key":"1361_CR87","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.fertnstert.2014.07.766","volume":"102","author":"MD Werner","year":"2014","unstructured":"Werner MD, Forman EJ, Hong KH, Franasiak JM, Molinaro TA, Scott RT. Defining the sweet spot for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles. Fertil Steril. 2014;102:1312\u20137.","journal-title":"Fertil Steril"},{"key":"1361_CR88","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/humrep\/del445","volume":"22","author":"J Smitz","year":"2007","unstructured":"Smitz J, Andersen AN, Devroey P, Arce J-C, MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22:676\u201387.","journal-title":"Hum Reprod"},{"key":"1361_CR89","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/humrep\/dez023","volume":"34","author":"N Friis Wang","year":"2019","unstructured":"Friis Wang N, Skouby SO, Humaidan P, Andersen CY. Response to ovulation trigger is correlated to late follicular phase progesterone levels: a hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise. Hum Reprod. 2019;34:942\u20138.","journal-title":"Hum Reprod"},{"key":"1361_CR90","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/humupd\/8.6.543","volume":"8","author":"M Filicori","year":"2002","unstructured":"Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update. 2002;8:543\u201357.","journal-title":"Hum Reprod Update"},{"key":"1361_CR91","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/humrep\/der380","volume":"27","author":"JN Hugues","year":"2012","unstructured":"Hugues JN. Impact of LH activity supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Hum Reprod. 2012;27:232\u201343.","journal-title":"Hum Reprod"},{"key":"1361_CR92","first-page":"5485","volume":"21","author":"A Rahman","year":"2017","unstructured":"Rahman A, Francomano D, Sagnella F, Lisi F, Manna C. The effect on clinical results of adding recombinant LH in late phase of ovarian stimulation of patients with repeated implantation failure: a pilot study. Eur Rev Med Pharmacol Sci. 2017;21:5485\u201390.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1361_CR93","first-page":"337","volume":"3","author":"BT Krause","year":"2009","unstructured":"Krause BT, Ohlinger R, Haase A. Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review. Biologics. 2009;3:337\u201347.","journal-title":"Biologics"},{"key":"1361_CR94","first-page":"996","volume":"35","author":"D Carone","year":"2012","unstructured":"Carone D, Caropreso C, Vitti A, Chiappetta R. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH\/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols. J Endocrinol Invest. 2012;35:996\u20131002.","journal-title":"J Endocrinol Invest"},{"key":"1361_CR95","first-page":"1507","volume":"83","author":"The European Recombinant Human LH Study Group","year":"1998","unstructured":"The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83:1507\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"1361_CR96","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0015-0282(16)55852-X","volume":"59","author":"Z Shoham","year":"1993","unstructured":"Shoham Z, Mannaerts B, Insler V, Coelingh-Bennink H. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril. 1993;59:738\u201342.","journal-title":"Fertil Steril"},{"key":"1361_CR97","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0015-0282(16)54715-3","volume":"56","author":"Z Shoham","year":"1991","unstructured":"Shoham Z, Balen A, Patel A, Jacobs HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril. 1991;56:1048\u201353.","journal-title":"Fertil Steril"},{"key":"1361_CR98","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/humrep\/16.12.2525","volume":"16","author":"S Burgu\u00e9s","year":"2001","unstructured":"Burgu\u00e9s S, Spanish Collaborative Group on Female Hypogonadotrophic Hypogonadism. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod. 2001;16:2525\u201332.","journal-title":"Hum Reprod"},{"key":"1361_CR99","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jogoh.2019.03.027","volume":"48","author":"K Huseyin","year":"2019","unstructured":"Huseyin K, Berk B, Tolga K, Eser O, Ali G, Murat A. Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism. J Gynecol Obstet Hum Reprod. 2019;48:833\u20138.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"1361_CR100","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1093\/humrep\/deac195","volume":"37","author":"A La Marca","year":"2022","unstructured":"La Marca A, Longo M. Extended LH administration as a strategy to increase the pool of recruitable antral follicles in hypothalamic amenorrhea: evidence from a case series. Hum Reprod. 2022;37:2655\u201361.","journal-title":"Hum Reprod"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-025-01361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-025-01361-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-025-01361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:04:41Z","timestamp":1747209881000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-025-01361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":100,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1186\/s12958-025-01361-8","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CA and PH declare receipt of unrestricted research grants from Merck; and lecture fees from Merck, MedEA, and Event Planet. AC declares lecture fees from Merck, MedEA, and Event Planet. LV and FC declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}